Drug intelligence / Profile preview

SCI-2213

Development stage: Preclinical
Lead developer: Scilex Holding
Modality: Small Molecules

Overview

SCI-2213 is an investigational drug candidate being developed by Scilex Holding Company. While specific pharmacological details and the exact molecular target have not been extensively disclosed in public clinical databases, it is part of Scilex's pipeline focused on non-opioid pain management and neurological conditions. The compound is currently in the early stages of development, following the company's strategy of identifying and developing targeted therapies for acute and chronic pain indications to provide alternatives to traditional opioid-based treatments.

Beyond the preview

Go deeper on SCI-2213.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCI-2213.

Explore the full profile